An Open-label Extension Study for Participants Who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)
Latest Information Update: 06 Feb 2025
At a glance
- Drugs Batoclimab (Primary)
- Indications Graves ophthalmopathy
- Focus Therapeutic Use
- Sponsors Immunovant
- 19 Dec 2024 Planned End Date changed from 1 Jun 2025 to 1 Aug 2026.
- 19 Dec 2024 Planned primary completion date changed from 1 May 2025 to 1 Aug 2026.
- 05 Dec 2023 Status changed from not yet recruiting to recruiting.